<- Go Home
Cryoport, Inc.
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions’ Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions’ Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Market Cap
$506.9M
Volume
561.5K
Cash and Equivalents
$49.7M
EBITDA
-$41.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$94.0M
Profit Margin
41.79%
52 Week High
$23.50
52 Week Low
$9.00
Dividend
N/A
Price / Book Value
1.14
Price / Earnings
-4.16
Price / Tangible Book Value
3.47
Enterprise Value
$501.5M
Enterprise Value / EBITDA
-14.85
Operating Income
-$69.9M
Return on Equity
21.87%
Return on Assets
-4.39
Cash and Short Term Investments
$448.5M
Debt
$414.9M
Equity
$472.2M
Revenue
$225.0M
Unlevered FCF
-$20.7M
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium